New Zealand - English - Medsafe (Medicines Safety Authority)

takeda new zealand limited - octocog alfa 2000 [iu];   - injection with diluent - 2000 iu - active: octocog alfa 2000 [iu]   excipient: calcium chloride dihydrate glutathione histidine mannitol polysorbate 80 sodium chloride trehalose dihydrate trometamol water for injection - advate is indicated for use in haemophilia a for prevention and control of haemorrhagic episodes. patients with haemophilia a may be treated with advate as perioperative management. advate is not indicated in von willebrand's disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

takeda new zealand limited - octocog alfa 250 [iu];   - injection with diluent - 250 iu - active: octocog alfa 250 [iu]   excipient: calcium chloride dihydrate glutathione histidine mannitol polysorbate 80 sodium chloride trehalose dihydrate trometamol water for injection - advate is indicated for use in haemophilia a for prevention and control of haemorrhagic episodes. patients with haemophilia a may be treated with advate as perioperative management. advate is not indicated in von willebrand's disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

takeda new zealand limited - octocog alfa 3000 [iu];   - injection with diluent - 3000 iu - active: octocog alfa 3000 [iu]   excipient: calcium chloride dihydrate glutathione histidine mannitol polysorbate 80 sodium chloride trehalose dihydrate trometamol water for injection - advate is indicated for use in haemophilia a for prevention and control of haemorrhagic episodes. patients with haemophilia a may be treated with advate as perioperative management. advate is not indicated in von willebrand's disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

takeda new zealand limited - octocog alfa 500 [iu];   - injection with diluent - 500 iu - active: octocog alfa 500 [iu]   excipient: calcium chloride dihydrate glutathione histidine mannitol polysorbate 80 sodium chloride trehalose dihydrate trometamol water for injection - advate is indicated for use in haemophilia a for prevention and control of haemorrhagic episodes. patients with haemophilia a may be treated with advate as perioperative management. advate is not indicated in von willebrand's disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

takeda new zealand limited - octocog alfa 4000 [iu];   - injection with diluent - 4000 iu - active: octocog alfa 4000 [iu]   excipient: calcium chloride dihydrate glutathione histidine mannitol polysorbate 80 sodium chloride trehalose dihydrate trometamol water for injection - advate is indicated for use in haemophilia a for prevention and control of haemorrhagic episodes. patients with haemophilia a may be treated with advate as perioperative management. advate is not indicated in von willebrand's disease.

European Union - English - EMA (European Medicines Agency)

swedish orphan biovitrum ab (publ) - efmoroctocog alfa - hemophilia a - antihemorrhagics - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency).

European Union - English - EMA (European Medicines Agency)

novo nordisk a/s - turoctocog alfa - hemophilia a - coagulation factor viii - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency). novoeight can be used for all age groups.

European Union - English - EMA (European Medicines Agency)

octapharma ab - simoctocog alfa - hemophilia a - blood coagulation factors - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency).nuwiq can be used for all age groups.

European Union - English - EMA (European Medicines Agency)

pfizer europe ma eeig - moroctocog alfa - hemophilia a - antihemorrhagics - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor-viii deficiency). refacto af is appropriate for use in adults and children of all ages, including newborns. refacto af does not contain von-willebrand factor, and hence is not indicated in von-willebrand's disease.,

European Union - English - EMA (European Medicines Agency)

csl behring gmbh - lonoctocog alfa - hemophilia a - antihemorrhagics - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency).afstyla can be used for all age groups.